van der Vorst MJDL, Neefjes ECW, Boddaert MSA, et al. – Researchers compared the olanzapine with haloperidol’s effectiveness and tolerability for the treatment of delirium in hospitalized patients with advanced cancer. They randomized (1:1) eligible adults (≥ with advanced cancer and delirium (Delirium Rating Scale-Revised-98 [DRS-R-98] total score ≥ 17.75) to receive either haloperidol or olanzapine (age-adjusted, titratable doses). Delirium response rate (DRR), defined as the number of patients with DRS-R-98 severity score < 15.25 and ≥ 4.5 points reduction, was assessed as the primary endpoint. The intention-to-treat analysis involved 98 patients. For olanzapine and for haloperidol, the DRRs were 45% and 57%, respectively, and mean times to response (TTR) was 4.5 days and 2.8 days, respectively. The occurrence of grade ≥ 3 treatment-related adverse events was reported in 5 patients (10.2%) in the olanzapine arm and in 10 patients (20.4%) in the haloperidol arm. Findings revealed no improvement of DRR or TTR with olanzapine treatment for delirium compared with haloperidol in hospitalized patients with advanced cancer.